Chapter 4. Road to ABT-869: A Multitargeted Receptor Tyrosine Kinase Inhibitor

  1. Rongshi Li and
  2. Jeffrey A. Stafford
  1. Michael Michaelides and
  2. Daniel H. Albert

Published Online: 28 SEP 2009

DOI: 10.1002/9780470524961.ch4

Kinase Inhibitor Drugs

Kinase Inhibitor Drugs

How to Cite

Michaelides, M. and Albert, D. H. (2009) Road to ABT-869: A Multitargeted Receptor Tyrosine Kinase Inhibitor, in Kinase Inhibitor Drugs (eds R. Li and J. A. Stafford), John Wiley & Sons, Inc., Hoboken, NJ, USA. doi: 10.1002/9780470524961.ch4

Editor Information

  1. Takeda San Diego, Inc., San Diego, CA 92121, USA

Author Information

  1. Abbott Laboratories, Abbott Park, IL 60064, USA

Publication History

  1. Published Online: 28 SEP 2009
  2. Published Print: 2 OCT 2009

Book Series:

  1. Wiley Series in Drug Discovery and Development

Book Series Editors:

  1. Binghe Wang

ISBN Information

Print ISBN: 9780470278291

Online ISBN: 9780470524961

SEARCH

Keywords:

  • road to ABT-869 - multitargeted receptor tyrosine kinase inhibitor;
  • alternate bicyclic heterocyclopyrimidines;
  • ABT-869 discovery in clinical trials for cancer treatment

Summary

This chapter contains sections titled:

  • Introduction

  • Early Lead Series

  • Drug Discovery Funnel

  • Characterization of ABT-869 and Advancement to Clinical Trials

  • Summary

  • Acknowledgments

  • References